Serum metabolomics in pulmonary sarcoidosis: metabolic signatures across prognoses
Abstract Background Sarcoidosis is a systemic inflammatory disease, primarily affecting the lungs, with a prognosis that varies widely among patients. While some patients recover spontaneously after diagnosis, others experience disease progression. Currently, the metabolomic profile associated with...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-08-01
|
| Series: | BMC Pulmonary Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12890-025-03863-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849238103182540800 |
|---|---|
| author | Dafu Zhu Jianglong Chen Li Zhang Hongxu Li Jingyi Wang Jiacui Song Dong Weng Pengcheng Zhang Qiuhong Li Yuan Zhang Mengmeng Zhao |
| author_facet | Dafu Zhu Jianglong Chen Li Zhang Hongxu Li Jingyi Wang Jiacui Song Dong Weng Pengcheng Zhang Qiuhong Li Yuan Zhang Mengmeng Zhao |
| author_sort | Dafu Zhu |
| collection | DOAJ |
| description | Abstract Background Sarcoidosis is a systemic inflammatory disease, primarily affecting the lungs, with a prognosis that varies widely among patients. While some patients recover spontaneously after diagnosis, others experience disease progression. Currently, the metabolomic profile associated with pulmonary sarcoidosis and its different clinical outcomes remains poorly understood. Methods Serum samples from 29 pulmonary sarcoidosis patients and 10 healthy controls were analyzed using untargeted UPLC-MS/MS metabolomics. Univariate and multivariate analyses identified differentially expressed metabolites, followed by pathway enrichment to evaluate their biological relevance. Patients were further stratified into self-healing (n = 11) and progressive (n = 18) subgroups based on prognosis. Differential metabolites between subgroups were compared, potential biomarkers were selected, and their diagnostic performance assessed. Correlations with clinical parameters were also analyzed to explore associations with disease progression. Results Sarcoidosis patients showed distinct serum metabolic profiles compared to healthy controls, with 10 upregulated and 199 downregulated metabolites. Pathway analysis indicated enrichment in amino acid, lipid, and immune-related pathways. Between prognostic subgroups, 25 differential metabolites were identified. Uric acid, testosterone sulfate, allopregnanolone sulfate, and 24,25-dihydroxyvitamin D3 emerged as key metabolites with prognostic value and moderate correlations with clinical parameters. Conclusions This study highlights distinct serum metabolic profiles associated with sarcoidosis prognosis, suggesting that specific metabolic alterations may aid in monitoring and predicting disease outcomes. These findings offer a foundation for future research into personalized treatment and management strategies. |
| format | Article |
| id | doaj-art-9f0135fe501d4d88a11f7beecd70979c |
| institution | Kabale University |
| issn | 1471-2466 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Pulmonary Medicine |
| spelling | doaj-art-9f0135fe501d4d88a11f7beecd70979c2025-08-20T04:01:44ZengBMCBMC Pulmonary Medicine1471-24662025-08-0125111210.1186/s12890-025-03863-ySerum metabolomics in pulmonary sarcoidosis: metabolic signatures across prognosesDafu Zhu0Jianglong Chen1Li Zhang2Hongxu Li3Jingyi Wang4Jiacui Song5Dong Weng6Pengcheng Zhang7Qiuhong Li8Yuan Zhang9Mengmeng Zhao10Department of Pulmonary and Critical Care Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji UniversitySchool of Biomedical Engineering, ShanghaiTech UniversityDepartment of Pulmonary and Critical Care Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji UniversitySchool of Biomedical Engineering, ShanghaiTech UniversitySchool of Medicine, Tongji UniversityDepartment of Pulmonary and Critical Care Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji UniversityDepartment of Pulmonary and Critical Care Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji UniversitySchool of Biomedical Engineering, ShanghaiTech UniversityDepartment of Pulmonary and Critical Care Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji UniversityDepartment of Pulmonary and Critical Care Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji UniversityDepartment of Pulmonary and Critical Care Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji UniversityAbstract Background Sarcoidosis is a systemic inflammatory disease, primarily affecting the lungs, with a prognosis that varies widely among patients. While some patients recover spontaneously after diagnosis, others experience disease progression. Currently, the metabolomic profile associated with pulmonary sarcoidosis and its different clinical outcomes remains poorly understood. Methods Serum samples from 29 pulmonary sarcoidosis patients and 10 healthy controls were analyzed using untargeted UPLC-MS/MS metabolomics. Univariate and multivariate analyses identified differentially expressed metabolites, followed by pathway enrichment to evaluate their biological relevance. Patients were further stratified into self-healing (n = 11) and progressive (n = 18) subgroups based on prognosis. Differential metabolites between subgroups were compared, potential biomarkers were selected, and their diagnostic performance assessed. Correlations with clinical parameters were also analyzed to explore associations with disease progression. Results Sarcoidosis patients showed distinct serum metabolic profiles compared to healthy controls, with 10 upregulated and 199 downregulated metabolites. Pathway analysis indicated enrichment in amino acid, lipid, and immune-related pathways. Between prognostic subgroups, 25 differential metabolites were identified. Uric acid, testosterone sulfate, allopregnanolone sulfate, and 24,25-dihydroxyvitamin D3 emerged as key metabolites with prognostic value and moderate correlations with clinical parameters. Conclusions This study highlights distinct serum metabolic profiles associated with sarcoidosis prognosis, suggesting that specific metabolic alterations may aid in monitoring and predicting disease outcomes. These findings offer a foundation for future research into personalized treatment and management strategies.https://doi.org/10.1186/s12890-025-03863-ySarcoidosisMetabolomicsPrognosisUPLC-MS/MSSerum |
| spellingShingle | Dafu Zhu Jianglong Chen Li Zhang Hongxu Li Jingyi Wang Jiacui Song Dong Weng Pengcheng Zhang Qiuhong Li Yuan Zhang Mengmeng Zhao Serum metabolomics in pulmonary sarcoidosis: metabolic signatures across prognoses BMC Pulmonary Medicine Sarcoidosis Metabolomics Prognosis UPLC-MS/MS Serum |
| title | Serum metabolomics in pulmonary sarcoidosis: metabolic signatures across prognoses |
| title_full | Serum metabolomics in pulmonary sarcoidosis: metabolic signatures across prognoses |
| title_fullStr | Serum metabolomics in pulmonary sarcoidosis: metabolic signatures across prognoses |
| title_full_unstemmed | Serum metabolomics in pulmonary sarcoidosis: metabolic signatures across prognoses |
| title_short | Serum metabolomics in pulmonary sarcoidosis: metabolic signatures across prognoses |
| title_sort | serum metabolomics in pulmonary sarcoidosis metabolic signatures across prognoses |
| topic | Sarcoidosis Metabolomics Prognosis UPLC-MS/MS Serum |
| url | https://doi.org/10.1186/s12890-025-03863-y |
| work_keys_str_mv | AT dafuzhu serummetabolomicsinpulmonarysarcoidosismetabolicsignaturesacrossprognoses AT jianglongchen serummetabolomicsinpulmonarysarcoidosismetabolicsignaturesacrossprognoses AT lizhang serummetabolomicsinpulmonarysarcoidosismetabolicsignaturesacrossprognoses AT hongxuli serummetabolomicsinpulmonarysarcoidosismetabolicsignaturesacrossprognoses AT jingyiwang serummetabolomicsinpulmonarysarcoidosismetabolicsignaturesacrossprognoses AT jiacuisong serummetabolomicsinpulmonarysarcoidosismetabolicsignaturesacrossprognoses AT dongweng serummetabolomicsinpulmonarysarcoidosismetabolicsignaturesacrossprognoses AT pengchengzhang serummetabolomicsinpulmonarysarcoidosismetabolicsignaturesacrossprognoses AT qiuhongli serummetabolomicsinpulmonarysarcoidosismetabolicsignaturesacrossprognoses AT yuanzhang serummetabolomicsinpulmonarysarcoidosismetabolicsignaturesacrossprognoses AT mengmengzhao serummetabolomicsinpulmonarysarcoidosismetabolicsignaturesacrossprognoses |